EXPERIENCE WITH VINCristINE - ASSOCIATED NEUROTOXICITY

N. A. OTHIENO-ABINYA and L. O. NYABOLA

ABSTRACT

Objectives: To evaluate the frequency and severity of occurrence of vincristine-associated neurotoxicity.

Design: A retrospective case series study

Setting: Hurlingham Oncology Clinic, Nairobi.

Subjects: Thirty-eight patients treated for various neoplasms with vincristine containing chemotherapeutic regimens.

Main outcome measures: The frequency and degree of neurotoxicity when vincristine was given at the standard dose of 1.4 mg/m².

Results: Five patients (13.2%) developed peripheral neuropathy, one having had it even before vincristine was started. Therefore only four (10.5%) had it attributed to vincristine. Four of the patients who developed neuropathy (80%) were HIV-positive. Neuropathy grade 2 (severe) occurred in only two patients leading to discontinuation of the drug. All the neurotoxicity resolved after discontinuation of vincristine.

Conclusion: Vincristine induced neuropathy occurred but was rarely severe at a dose of 1.4 mg/m². It appeared to be more frequent in HIV infected individuals, but controlled studies with bigger sample sizes are required to determine whether this may warrant routine capping of the dose at a maximum of 2 mg.

INTRODUCTION

Vincristine is one of the oldest cytotoxic agents in clinical use. It has a broad spectrum of anticancer activity, with a recommended dose of 1.4 mg/m² administered intravenously. Administrations are repeated twice weekly or three weekly depending on the particular regimen employed. Peripheral neurotoxicity is the most frequent and dose-limiting toxicity of vincristine(1,2). When used in combination with mustine hydrochloride, prednisone and procarbazine (MOPP) protocol used in the treatment of Hodgkin’s lymphoma in its original description(3-5), high remission rates and long-term relapse-free survivals were realised. However, when the dose is capped at the upper limit of 2 mg as recommended by Moore et al at Stanford (6), relapse-free survival is attenuated as experienced by Bakemeier and colleagues of ECOG(7).

Vincristine is one of the cheapest of cytotoxic drugs, costing about 18 US Dollars per adult dose in Kenya on average. Its optimum use is therefore a matter of great oncologic importance, especially in economically disadvantaged settings. We routinely administer vincristine at full doses calculated at 1.4 mg/m² to maintain the right dose-intensity, except in purely palliative treatments.

MATERIALS AND METHODS

A retrospective analysis of data on patients treated with vincristine containing regimens in our clinic between December 1992 and May 1999 was carried out. Details of age at commencement of treatment, sex, histology, evidence of human immunodeficiency virus (HIV) infection, treatment regimen employed, evidence of neurotoxicity, type of neurotoxicity, course of treatment at which neurotoxicity was first experienced, grade of neurotoxicity, treatment adjustment following neurotoxicity and neurotoxicity response to treatment discontinuation. From this information, cumulative dose of vincristine at which neurotoxicity was first recorded was derived. Peripheral neurotoxicity was graded according to World Health Organization (WHO) toxicity criteria (Grade 0 - none observed, grade 1 - paraesthesias and/or decreased tendon reflexes, grade 2 - severe paraesthesias and/or mild weakness, grade 3 - intolerable paraesthesias and/or marked motor loss, grade 4 - paralysis). Fisher’s exact test and the Z test were used to compare neurotoxicity between HIV positive and negative cases.

RESULTS

Records were evaluated for a total of 38 patients; 25 males and 13 females. The age range was 16-72 years, with a median age of 38 years. Sixteen patients tested positive for HIV infection while 22 were negative. Twenty-
two patients had histologic diagnosis of malignant lymphomas, 12 had epidemic Kaposi's sarcoma, two soft tissue sarcomas, one multiple myeloma and one anaplastic carcinoma. The median dose of vincristine per treatment was 2 mg and the mean dose per treatment was 2.2 mg. The dose range per treatment was 2.0 - 2.8 mg.

Five patients (13.2%) had documented peripheral neuropathy and their details are included in Table 1. Their ages ranged between 16 and 45 years and the median age was 30 years. Of these five patients one had neuropathy even before vincristine was started. She had been on zidovudine, didanosine and saquinavir. Only four (10.5%) had neuropathy attributable to vincristine. Two patients had neuropathy severe enough to have vincristine discontinued. A third patient had moderate neuropathy but demanded the discontinuation of vincristine after having been informed that it was most probably responsible for the symptoms. All cases of neurotoxicity resolved after discontinuation of vincristine even the case in whom it had been recorded before its initiation.

<table>
<thead>
<tr>
<th>Protocol</th>
<th>No. of patients</th>
<th>No. with neuropathy</th>
<th>Vincristine course at which neuropathy occurred</th>
<th>Grade of neuropathy</th>
<th>Vincristine stopped?</th>
<th>For neuropathy cases, intercurrent HIV infection</th>
<th>For neuropathy Vincristine dose per treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>COP</td>
<td>16</td>
<td>1</td>
<td>4</td>
<td>Moderate</td>
<td>Yes</td>
<td>Yes</td>
<td>2.6 mg</td>
</tr>
<tr>
<td>M-CHOP</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>Mild</td>
<td>No</td>
<td>No</td>
<td>2.0 mg</td>
</tr>
<tr>
<td>ABV</td>
<td>5</td>
<td>1</td>
<td>3</td>
<td>Severe</td>
<td>Yes</td>
<td>Yes</td>
<td>2.0 mg</td>
</tr>
<tr>
<td>BV</td>
<td>5</td>
<td>0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>MACOP-B</td>
<td>6</td>
<td>1*</td>
<td>Severe at 2</td>
<td>Severe</td>
<td>Yes</td>
<td>Yes</td>
<td>2 mg</td>
</tr>
<tr>
<td>VAC</td>
<td>2</td>
<td>0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>BE-BVE</td>
<td>1</td>
<td>1**</td>
<td>&gt;20</td>
<td>Mild</td>
<td>No</td>
<td>Yes</td>
<td>2 mg</td>
</tr>
<tr>
<td>Others</td>
<td>2</td>
<td>0</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*Developed neuropathy even before vincristine was started
**First had vincristine as a single agent many times.

Four of the patients who had neuropathy (80%) had tested positive for HIV infection. Only one out of 22 HIV-negative patients (4.5%) developed neuropathy, but these differences were not statistically significant (Z=1.841, P>0.05). Twenty-five per cent of HIV-positive patients developed neuropathy compared with only 4.5% of HIV negative patients. The difference was however not statistically significant (P=0.09). The dose range per treatment was 2.2 mg. The cumulative dose at the time of vincristine associated peripheral neurotoxicity ranged between 4 to >40 mg.

DISCUSSION

Vincristine is virtually devoid of myelotoxicity, making it quite appropriate in combination chemotherapy. Peripheral neurotoxicity which is its most frequent dose

Routine capping of vincristine dose at a maximum of 2 mg as recommended by the Stanford group because of fear of neurotoxicity results in a dose only suitable for persons smaller than 1.43 m<sup>2</sup> and this has been shown to have deleterious effects on outcome(6,10). A re-evaluation of full doses of vincristine regardless of body size was done in another study and confirmed the original NCI conclusion that use of full doses is feasible(11). Caution needs to be exercised when the drug is used in intensive weekly schedules such as previously adopted in combination with cyclophosphamide and prednisone (CVP)(12) which appeared to be more frequently associated with neurotoxicity (personal observations). None of our patients was treated with the weekly CVP combination. There are also antecedent neurologic disorders such as Charcot-Marie-Tooth disease, hereditary and sensory neuropathy type 1, and childhood poliomyelitis in which
the use of vincristine should be discouraged(13,14). None of our patients had any of these.

Vincristine-associated neurotoxicity occurs fairly frequently but appears to be rarely severe. The neuropathy tends to be more common in individuals infected with HIV. Whether this warrants routine capping of the dose of vincristine to a maximum of 2mg needs to be addressed in a prospective study with a large sample size.

ACKNOWLEDGEMENTS

To Susanne Mwongera of Hurlingham Oncology Clinic for her excellent record keeping.

REFERENCES